EnginZyme Secures €6.4 Million Series A Financing Round Led by Sofinnova Partners
22.4.2020 09:00:00 EEST | Business Wire | Press release
EnginZyme, the cell-free synthetic biology company, today announced a Series A investment of €6.4 million led by Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, bringing the company’s total funding to over €10 million since 2014.
The funds will be used to accelerate the development of EnginZyme’s technology platform and take its first internal production process to pilot. The company also announced that Michael Krel, Partner of the Sofinnova Industrial Biotech Fund, will join EnginZyme’s Board of Directors.
“Sofinnova Partners brings a deep industrial experience, which makes them the perfect partner for us,” said EnginZyme CEO Dr. Karim Engelmark Cassimjee. “This is a complex field, so it is important to have investors that can provide not only the financial support but also strategic guidance. With over a decade of experience investing in industrial biotechnology, there are few investors as well placed as Sofinnova Partners to bring this domain expertise to the table.”
“There's never been a more important time to provide solid, long-term support to pioneering companies in industrial biotechnology,” said Michael Krel, Partner of the Sofinnova Industrial Biotech Fund. “We strongly believe in EnginZyme’s outstanding team and the potential of its technology to join the power of biology with the efficiency of chemical engineering to bring us towards a more sustainable future.”
EnginZyme seeks to solve one of the fundamental problems of our time: How to produce sustainable alternatives to plastics, nylons, rubbers, and the tons of other synthetics that are used on a daily basis, without compromising on cost-effectiveness. To achieve this, EnginZyme’s technology platform combines the breadth and power of nature (enzymatic cascades) with the efficiency of the chemical industry (packed bed reactors) in a best-of-both-worlds technical solution.
“It has long been recognized that if we could effectively access nature’s full palette of molecules, we could solve many of the world’s most pressing problems,” said Dr. Engelmark Cassimjee. “There’s just so much more you can do with biological systems than with traditional catalysts and petroleum-based building blocks. But the key word here is ‘effectively’ — it needs to be as cheap and easy to scale as the chemical solutions we’ve used for more than a century now. We’re the first company to truly address that and by doing so we are building foundational technology for an entire future industry.”
About EnginZyme
EnginZyme’s cell-free synthetic biology platform marries the efficiency of the chemical industry with the power and diversity of biology. The company was founded in Stockholm, Sweden. Since its start in 2014 it has used its technology to provide R&D services to leading companies in multiple industries, such as pharma, food, chemicals and flavors & fragrances. Its long-term aim is to make its cell-free synbio platform the foundation upon which the future chemical industry rests.
For more information, please visit: www.enginzyme.com
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, with offices in London and Milan, the firm brings together a team of 40 professionals from all over Europe, the U.S. and Asia. The firm focuses on paradigm-shifting technologies alongside visionary entrepreneurs. Sofinnova Partners invests across the Life Sciences value chain as a lead or cornerstone investor, from very early-stage opportunities to late-stage/public companies. It has backed nearly 500 companies over more than 48 years, creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management.
For more information, please visit: www.sofinnovapartners.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200421005045/en/
Contact information
Beatrix Ellis
press@enginzyme.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enginzyme Raises SEK 75 Million to Advance Its Commercial Biomanufacturing Strategy23.9.2026 15:07:00 EEST | Press release
Enginzyme AB has closed a new equity round raising SEK 75 million. The round marks a key milestone in the company's shift from R&D to a commercially driven strategy. "With our growth strategy established, closing this new investment round was a priority for enginzyme," said Aymeric de Gantes, enginzyme's CEO. "We are also very excited to welcome new shareholders with complementary expertise, who will all contribute to our mission to deliver biomanufacturing solutions for the personal care, food, and pharmaceutical industries. Our technology enables lower cost in use for higher-quality ingredients, obtained through more sustainable manufacturing processes." Lotus One Investment Pte. Ltd. and Valquest Partners Europe are joining the company as new shareholders and members of the Board of Directors. Sofinnova Partners, Stiftelsen Industrifonden, Navigare Ventures AB and Almi Invest GreenTech were key participants, combined with several other new and existing shareholders. On Thursday, Sep
SLB Awarded Major Contract by OQEP for Integrated Facility Expansion in Oman23.9.2026 15:04:00 EEST | Press release
SLB (NYSE: SLB) has been awarded a contract by OQ Exploration & Production (OQEP) to deliver the Bisat-B Expansion Production Facility in Oman. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922635677/en/ SLB has been awarded a contract by OQ Exploration & Production (OQEP) to deliver the Bisat-B Expansion Production Facility in Oman. Under the contract, SLB will provide design, engineering, procurement, construction and commissioning services for the facility, along with four years of operations and maintenance support. Under the contract, SLB will provide design, engineering, procurement, construction and commissioning services for the facility, along with four years of operations and maintenance support. The expansion will increase the facility’s gross fluids handling capacity to 548,000 barrels per day. The project is scheduled for completion within 19 months. The award marks the next phase of development for the Bisa
Datavault AI Announces Rights Offering to Shareholders23.9.2026 15:03:00 EEST | Press release
Datavault AI Inc. (Nasdaq: DVLT) (“Datavault AI” or the “Company”), an Artificial Intelligence Platform (“AIP”) company providing data monetization, credentialing and tokenization technologies, today announced that its board of directors (the “Board”) has approved a rights offering to holders of its common stock (“Common Stock”) and certain other Datavault AI securities. Moody Capital Solutions, Inc. (“Moody Capital”) will act as dealer manager for the rights offering. The Rights Offering to include investors in a process usually reserved exclusively for banks Under the rights offering, the Company will distribute, at no charge, transferable subscription rights to holders of record of Common Stock and certain other Company securities with a contractual right to participate in the distribution. The Company has set a record date of October 9, 2026 for such offering (the “Record Date”). Such holders will receive one subscription right for a Common Unit for each share of Common Stock owned
Copeland Completes Acquisition of Dickson, Advancing Cold Chain Intelligence for Healthcare and Life Sciences23.9.2026 15:00:00 EEST | Press release
Copeland, a global leader in compression technologies and controls solutions, today announced it has completed the acquisition of Dickson, a Chicago-based provider of environmental monitoring and compliance technology solutions for highly regulated life sciences and healthcare environments. Increasing regulatory demands across the pharmaceutical and life sciences cold chain require continuous visibility from production through final delivery. Together, Dickson’s cloud-native monitoring platform and Copeland’s controls, monitoring and enterprise software solutions will enable a more connected, intelligent and compliant cold chain. “We are pleased to welcome our new colleagues from Dickson into Copeland,” said Ross B. Shuster, CEO of Copeland. “The acquisition of Dickson further strengthens our ability to serve customers across every stage of the healthcare and life sciences cold chain, from pharmaceutical manufacturing through distribution and patient care.” Enabling a Smarter, More Con
Sitetracker and 5x5 Break the Price Barrier for Portfolio-Scale Digital Twins and Asset Intelligence23.9.2026 13:11:00 EEST | Press release
Sitetracker and 5x5 Technologies today introduced a data-to-twin workflow that gives wireless infrastructure owners a practical, affordable path to digitizing an entire tower portfolio. The Sitetracker platform now integrates 5x5 Synthetic Twin technology, providing scalable asset intelligence at a price up to 85% less than traditional site modeling methods. Synthetic Twins leverage Sitetracker’s leading tower portfolio and operational data to create interactive 3D models of towers, rooftops and ground compounds providing tower operators with a baseline of their portfolio that can be progressively enriched as the site conditions evolve. This data when combined with Scout, Sitetracker’s Agentic AI platform, opens the opportunity for digitized workflows and unparalleled understanding of the asset portfolio. Why it matters AI-driven data demand, more spectrum deployments, and denser infrastructure are raising the bar for tower operations. Towercos need precise knowledge of each site: what
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom